Hoffmann-La Roche
5-FU/LV(Hoffmann-La Roche)은 Colorectal Cancer 표적 치료제로, Colorectal Cancer 영역에서 개발·상용화 중입니다. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 5% (ClinicalTrials.gov NCT01581307). 차별점: novel liposomal irinotecan) in combination with 5-FU/LV and oxaliplatin for treatment-naive patients with unresectable locall.
Colorectal Cancer
Colorectal Cancer
Active
SN-38 by carboxylesterase enzymes and inactiv
novel liposomal irinotecan) in combination with 5-FU/LV and oxaliplatin for treatment-naive patients with unresectable locall
topoisomerase 1 cleavage complexes (Top1cc) and DNA double-strand breaks (DSBs) were determined by immunofluorescence
biomarker for systemic treatment in patients with metastatic colorectal cancer
resistance to 5-FU/LV in colorectal cancer cells through downregulation of the c-Myc/ABCB5 axis
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Hoffmann-La Roche
5-FU/LV(Hoffmann-La Roche)은 Colorectal Cancer 표적 치료제로, Colorectal Cancer 영역에서 개발·상용화 중입니다. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 5% (ClinicalTrials.gov NCT01581307). 차별점: novel liposomal irinotecan) in combination with 5-FU/LV and oxaliplatin for treatment-naive patients with unresectable locall.
Colorectal Cancer
Colorectal Cancer
Active
SN-38 by carboxylesterase enzymes and inactiv
novel liposomal irinotecan) in combination with 5-FU/LV and oxaliplatin for treatment-naive patients with unresectable locall
topoisomerase 1 cleavage complexes (Top1cc) and DNA double-strand breaks (DSBs) were determined by immunofluorescence
biomarker for systemic treatment in patients with metastatic colorectal cancer
resistance to 5-FU/LV in colorectal cancer cells through downregulation of the c-Myc/ABCB5 axis
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.